A Phase 3 interventional study of Vutrisiran in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals. Enrolling by invitation at 87 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Alnylam Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals — 2 open to participants now, 4 under way, 2 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Alnylam Pharmaceuticals.
Among the 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals, this one is one of 2 that started in 2024, is one of 7 in phase 3, and was the 12th registered.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →2 of the 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in United States, Brazil, Bulgaria and 9 more countries
By country, each count listing its studies:
Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 700 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Median enrollment 216 across the 8 interventional studies, 346 across the 3 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M).
Drug: Vutrisiran
Vutrisiran administered SC q3M
Also known as: ALN-TTRSC02, AMVUTTRA®
Frequency of Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 36 Months
Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)
The KCCQ is a 23-item self-administered questionnaire quantifying 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary \[OS\]). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time frame: Baseline up to 36 Months
Change from Baseline in New York Heart Association (NYHA) Class
NYHA classification grades the severity of heart failure symptoms into the following stages: I (no symptoms; ordinary physical activity such as walking and climbing stairs does not cause fatigue or dyspnea), II (symptoms with ordinary physical activity; walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, in cold weather, in wind or when under emotional stress causes undue fatigue or dyspnea), III (symptoms with less than ordinary physical activity; walking 1 to 2 blocks on the level and climbing more than 1 flight of stairs in normal conditions causes undue fatigue or dyspnea), IV (symptoms at rest; inability to carry on any physical activity without fatigue or dyspnea).
Time frame: Baseline up to 36 Months
Change From Baseline in the Cardiac Biomarker: N-terminal Prohormone of B-type Natriuretic Peptide (NT-proBNP)
NT-proBNP will be assessed through measurement of serum levels.
Time frame: Baseline up to 36 Months
Change From Baseline in the Cardiac Biomarker: Troponin I
Troponin I will be assessed through measurement of serum levels.
Time frame: Baseline up to 36 Months
All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits)
All deaths, hospitalizations and urgent HF visits will be recorded throughout the study as part of SAE and AE monitoring
Time frame: Up to 36 Months
Change from baseline in serum TTR level
Time frame: Baseline, Month 6 and Month 12
Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Started Dec 2024 (actual). Primary completion is estimated for Mar 2028, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vutrisiran
Amyloidosis, Hereditary, Transthyretin-Related →